BW

CommScope’s Innovative Set Top Will Provide Orange Moldova’s Subscribers with Both Live and Streaming Viewing Options

HICKORY, N.C.--(BUSINESS WIRE)--#AndroidTV--CommScope, a global leader in home network solutions, has partnered with Orange Moldova to provide their subscribers with the latest generation of set tops powered by Android TV™ designed to provide both live television and premium streaming services. With the launch of the Orange TV Box 4K, Orange…
Leer más...

Ruth Health Secures $2.4M Seed Round Led by Giant Ventures to Reimagine Comprehensive Prenatal & Postpartum Care for American Women

Infusion of capital will help scale the telehealth platform’s virtual healthcare services while empowering, educating, and increasing accessibility for birthing people and their families LOS ANGELES--(BUSINESS WIRE)--#PostpartumCare--Ruth Health, the progressive telehealth and comprehensive care platform built for women by women, is proud to announce its $2.4 million seed funding round…
Leer más...

The Arena Group Anticipates Preliminary Revenue of Approximately $47 Million for the First Quarter of 2022

Revenue Expected to Significantly Exceed Published Wall Street Expectations; Company to Announce First Quarter Results and Host Conference Call on May 4, 2022 NEW YORK--(BUSINESS WIRE)--The Arena Group Holdings, Inc. (NYSE American: AREN) (the “Company”) or “The Arena Group”), a tech-powered media company with 40 owned and operated properties and…
Leer más...

Adverity Launches on Google Cloud Marketplace

NEW YORK & LONDON--(BUSINESS WIRE)--Adverity, a leading data and analytics platform for marketing, sales and e-commerce teams, has today launched on Google Cloud Marketplace. The Adverity solution is now available to all Google Cloud customers. Google Cloud customers will have the ability to access Adverity’s state-of-art data integration capabilities directly…
Leer más...

FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)

- Approval of VIVJOA™ marks a significant therapeutic advancement for reducing the incidence of RVVC, a condition with substantial unmet need, in permanently infertile and postmenopausal women - VIVJOA™ is the first FDA approval in Mycovia’s pipeline of novel treatments for fungal infections - U.S. commercial launch of VIVJOA™ expected…
Leer más...